The National Institute of Biomedical Research and Ridgeback Biotherapeutics Respond to 16th Ebola Outbreak in the Democratic Republic of Congo [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
Congo (DRC) has declared an outbreak of Ebola virus disease (EVD) in Kasai Province after samples tested at the National Institute of Biomedical Research (INRB) in Kinshasa confirmed the cause of the EVD outbreak as Orthoebolavirus zairense (EBOV) (formerly, Zaire ebolavirus). Infection cause by Orthoebolavirus zairense , referred to as Ebola virus disease (EVD), is severe and often fatal with case fatality rates ranging from 25% to 90%, and is transmitted via bodily fluids, zoonotic transmission, or contact with contaminated surfaces. www.ridgebackbio.com As of this press release, there have been 25 laboratory-confirmed cases, among them 14 deaths. Patients came from Bulape and Mweka health zones in Kasai Province and presented with symptoms including fever, asthenia, vomiting, and hemorrhage. The INRB in collaboration with Ridgeback Biotherapeutics ("Ridgeback") announces the deployment of their emergency response team to the Kasai Province to treat individuals with EBOV-infec
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EBS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone AccessGlobeNewswire
- Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 10/29/25 - Beat
EBS
Sec Filings
- 12/5/25 - Form 144
- 11/12/25 - Form 4
- 11/12/25 - Form 8-K
- EBS's page on the SEC website